Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.

Retinoids can prevent skin cancer in high-risk people but have side effects and require more research on dosing and effectiveness.

Chemotherapy may cause recurring hair loss due to an autoimmune response.

Hair loss can be caused by stress, infections, drugs, and various diseases, with treatment depending on accurate diagnosis.

Some drugs can cause skin, nail, and hair problems, which are important for healthcare professionals to recognize and report.

Microneedle technology has improved drug delivery and patient comfort but needs more research for broader use.

Thyroid hormones are important for skin health and changes in them can affect conditions like hair loss and eczema.

Thyroid diseases may contribute to autoimmune skin diseases, and more research is needed on their relationship.

Using systemic drugs as creams for skin conditions shows promise, but more research is needed to confirm their effectiveness and safety.

Tamoxifen caused hair loss in a 52-year-old woman.

Gray hair regained color after thyroid hormone treatment.

A patient with Cronkhite-Canada Syndrome developed colon cancer that spread to the liver, showing the need for regular cancer checks in such patients.

Skin reactions are a common reason for emergency visits due to drug allergies, with some severe cases needing intensive care.

Off-label drug use can be risky but sometimes beneficial when standard treatments fail.

Keratins help protect cells, aid in cancer diagnosis, and influence cancer behavior and treatment.

DrugNet effectively identifies new uses for existing drugs and may save resources in drug development.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.

Finasteride affects UGT1A4 enzyme, but not enough to cause issues when combined with other drugs.

The document concludes that reactivation of herpesviruses, especially HHV-6, is linked to severe symptoms and complications in drug-induced hypersensitivity syndrome.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Dutasteride is a safe and effective treatment for hair loss.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

Endocrine therapies for cancer significantly increase the risk of hair loss.